Celldex Therapeutics, Inc. CLDX
Set alert
29.61 USD +0.57 +1.96%
As of Nov 3, 1:53 PM ET
28.67 Day range 29.95
22.10 52-week range 45.14
- YTD
- +9.02%
- 1 year
- +19.64%
- Open
- 29.36
- Prev close
- 29.04
- Mkt cap
- 2.34B
- Vol
- 320.93K
- Avg vol
- 1.34M
- EPS
- -4.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.67
- High
- 29.95
- Forward P/E
- -6.83
- Beta
- 1.03
- Short ratio
- 4.27
- Inst. own
- 109.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 34.06
- 200-d avg
- 32.65
- 1y target
- 63.07
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 63.07 +113.0% upside
Now 29.61
- Target (low)
- 28.00
- Target (mean)
- 63.07
- Target (high)
- 100.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 16
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.01 | -1.07 – -0.94 | -1.01 | -0.1% | 883.22K | 0.0% | 10 |
| Next quarter | -1.01 | -1.12 – -0.87 | -1.22 | +17.2% | 1.22M | +911.2% | 10 |
| Current year | -4.12 | -4.33 – -3.71 | -3.90 | -5.7% | 1.85M | +19.7% | 10 |
| Next year | -4.25 | -5.00 – -3.26 | -4.12 | -3.1% | 8.76M | +373.5% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 23, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 22, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 22, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 10, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 29, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 22, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 22, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 22, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jul 22, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 20, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jun 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 10, 2026 | UBS | Maintained | Buy | Buy |
| May 13, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 8, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 20, 2026 | Barclays | Upgrade | Underweight | Overweight |
| Mar 2, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 26, 2026 | Stifel | Reiterated | Buy | Buy |
| Dec 17, 2025 | Barclays | Maintained | Underweight | Underweight |
| Nov 11, 2025 | Barclays | Maintained | Underweight | Underweight |
| Oct 21, 2025 | Mizuho | Initiated | — | Outperform |
| Oct 13, 2025 | Barclays | Initiated | — | Underweight |
| Sep 17, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 20, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 20, 2025 | Citigroup | Maintained | Buy | Buy |
| Aug 20, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 20, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |